Revolution Medicines Stock Performance
| RVMD Stock | USD 57.50 0.75 1.32% |
On a scale of 0 to 100, Revolution Medicines holds a performance score of 15. The company holds a Beta of 1.14, which implies a somewhat significant risk relative to the market. Revolution Medicines returns are very sensitive to returns on the market. As the market goes up or down, Revolution Medicines is expected to follow. Please check Revolution Medicines' kurtosis, and the relationship between the downside variance and day median price , to make a quick decision on whether Revolution Medicines' historical price patterns will revert.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Revolution Medicines are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Revolution Medicines exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.85 | Five Day Return 1.8 | Year To Date Return 107.46 | Ten Year Return 102.65 | All Time Return 102.65 |
1 | Disposition of 16667 shares by Kelsey Stephen Michael of Revolution Medicines at 4.09 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 1454 shares by Cislini Jeff of Revolution Medicines at 44.1853 subject to Rule 16b-3 | 09/16/2024 |
3 | Revolution Medicines director sells 249,716 in company stock | 10/10/2024 |
4 | Disposition of 6000 shares by Cislini Jeff of Revolution Medicines at 36.57 subject to Rule 16b-3 | 10/11/2024 |
5 | Disposition of 16666 shares by Kelsey Stephen Michael of Revolution Medicines at 4.09 subject to Rule 16b-3 | 10/14/2024 |
6 | Revolution Medicines, Inc. Receives Average Recommendation of Buy from Analysts | 10/24/2024 |
7 | Disposition of 2022 shares by Mark Goldsmith of Revolution Medicines at 45.4566 subject to Rule 16b-3 | 10/25/2024 |
8 | Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - Yahoo Finance | 10/30/2024 |
9 | Disposition of 5000 shares by Patel Sushil of Revolution Medicines at 24.84 subject to Rule 16b-3 | 10/31/2024 |
10 | Disposition of 5000 shares by Mark Goldsmith of Revolution Medicines at 55.0268 subject to Rule 16b-3 | 11/01/2024 |
11 | Disposition of 36600 shares by Mark Goldsmith of Revolution Medicines at 0.49 subject to Rule 16b-3 | 11/04/2024 |
12 | Revolution Medicines Inc Q3 2024 Earnings Report Preview What To Look For | 11/05/2024 |
13 | Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress | 11/06/2024 |
14 | What is HC Wainwrights Estimate for RVMD Q3 Earnings | 11/07/2024 |
15 | Wellington Management Group LLP Reduces Stake in Revolution Medicines Inc | 11/08/2024 |
16 | Revolution Medicines executive sells shares worth 977,508 | 11/15/2024 |
17 | Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. - MarketBeat | 11/19/2024 |
| Begin Period Cash Flow | 163.1 M |
Revolution |
Revolution Medicines Relative Risk vs. Return Landscape
If you would invest 4,265 in Revolution Medicines on August 28, 2024 and sell it today you would earn a total of 1,485 from holding Revolution Medicines or generate 34.82% return on investment over 90 days. Revolution Medicines is currently generating 0.5075% in daily expected returns and assumes 2.5614% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Revolution, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revolution Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revolution Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revolution Medicines, and traders can use it to determine the average amount a Revolution Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1981
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RVMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.56 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Revolution Medicines is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revolution Medicines by adding it to a well-diversified portfolio.
Revolution Medicines Fundamentals Growth
Revolution Stock prices reflect investors' perceptions of the future prospects and financial health of Revolution Medicines, and Revolution Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revolution Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (845.95) % | ||||
| Current Valuation | 8.21 B | ||||
| Shares Outstanding | 168.22 M | ||||
| Price To Book | 6.09 X | ||||
| Price To Sales | 13,036 X | ||||
| Revenue | 11.58 M | ||||
| Gross Profit | (217.69 M) | ||||
| EBITDA | (430.58 M) | ||||
| Net Income | (436.37 M) | ||||
| Cash And Equivalents | 461.43 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 87.94 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 9.34 X | ||||
| Cash Flow From Operations | (350.57 M) | ||||
| Earnings Per Share | (3.71) X | ||||
| Market Capitalization | 9.67 B | ||||
| Total Asset | 2.06 B | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 1.74 B | ||||
About Revolution Medicines Performance
By analyzing Revolution Medicines' fundamental ratios, stakeholders can gain valuable insights into Revolution Medicines' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revolution Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revolution Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.24) | (0.25) |
Things to note about Revolution Medicines performance evaluation
Checking the ongoing alerts about Revolution Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revolution Medicines help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 11.58 M. Net Loss for the year was (436.37 M) with loss before overhead, payroll, taxes, and interest of (217.69 M). | |
| Revolution Medicines currently holds about 461.43 M in cash with (350.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26. | |
| Revolution Medicines has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Victory Capital Management Inc. Sells 104,851 Shares of Revolution Medicines, Inc. - MarketBeat |
- Analyzing Revolution Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revolution Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Revolution Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revolution Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revolution Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revolution Medicines' stock. These opinions can provide insight into Revolution Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |